Postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility (EORTC Protocol 11961)

Strahlentherapie und Onkologie

Volumn 175, Issue SUPPL. 2, 1999, Pages 111-114

  Hideghéty, Katalin ^a   Sauerwein, Wolfgang ^b   Haselsberger, Klaus ^b   Grochulla, Frank ^b   Fankhauser, Heinz ^b   Moss, Raymond ^b   Huiskamp, René ^b   Gabel, Detlef ^b   De Vries, Martin ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b NONE

Author keywords

BNCT; BSH; Glioblastoma; Phase I study

Indexed keywords

BORON 10; HELIUM; LITHIUM;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; EUROPE; GLIOBLASTOMA; HUMAN; NETHERLANDS; NEUTRON CAPTURE THERAPY; NEUTRON RADIATION; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; RADIATION DOSE; SAFETY;

EID: 0345580196     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03038907     Document Type: Conference Paper

References (17)

1. Ceberg CP, Brun A, Kahl SB, et al. A comparative study on the farmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulphydril boron hydride (BSH) in thr RG2 rat glioma model. J Neurosurg 1995;83:86-92.
2. Ceberg CP, Persson A, Brun A, et al. Performance of BSH in patients with astrocytoma grades III-IV - a basis for boron neutron capture therapy. J Neurosurg 1995;83:79-85.
3. European Organization for Research and Treatment of Cancer BNCT Study Group. Protocol 11961 Postoperative Treatment of Glioblastoma with BNCT at the Petten Irradiation Facility Phase I Clinical Trial, 1996.
4. Fankhauser H, Stragliotto G, Zbinden P. Borocaptate sodium (BSH) pharmacokinetics in glioma patients. In: Gabel D, Moss RL (eds.). Boron Neutron Capture Therapy. Toward Clinical Trials of Glioma Treatment. New York, Plenum Press, 1992;155-62.
5. Gavin PR, Huiskamp R, Wheele, FJ, et al. Large animal normal tissue tolerance using an epithermal neutron beam and borocaptate sodium. Strahlenther Onkol 1993;169:48-5.
6. 11SH (BSH) in Patients with Malignant Glioma as Precondition for Boron Neutron Capture Therapy (BNCT). Int J Radiat Oncol Biol Phys 1994; 28:1175-81.
7. Haritz D, Piscol K, Gabel D. The biodistribution of BSH in patients with malignant glioma. In: Allen BJ, Moore DE, Harrington BV (eds.). Progress in Neutron Capture Therapy for Cancer. New York, Plenum Press, 1992;557-60.
8. 11SH in patients with glioblastoma. Cancer Res 1994;54:6318-20.
9. Hatanaka H, Nakagawa Y. Clinical resultsof Long-surviving Brain Tumor Patients Who Underwent Boron Neutron Capture Therapy. Int J Radiat Oncol Biol Phys 1994;28:1061-6.
10. Mehta SC, Lu DR. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharm Drug Dispos 1995;16:735-44.
11. Moss RL, Casado J, Ravensberg K, et al. The completed BNCT facility at HFR Petten In: Abstracts of the Seventh International Symposium on Neutron Capture Therapy for Cancer. p: 135 Zürich, 4-7 September, 1996.
12. Nakagawa Y, Kyonghon P, Kitamura K, et al. What were important factors in patient's treated by boron neutron capture therapy in Japan In: Abstracts of the Seventh International Symposium on Neutron Capture Therapy for Cancer. p: 164 Zürich, 4-7 September, 1996.
13. 11SH to tumor tissue of glioma patients in boron neutron capture therapy. In: Mishima Y (ed.). Neutron Capture Therapy for Human Cancers. New York, Plenum Press, 1995, submitted.
14. Pavy J-J, Denekamp J, Letschert J, et al. EORTC late effects working group Late effects toxicity scoring: the SOMA scale.
15. Sauerwein W. The clinical project at HFR Petten - A status report. In: Abstracts of the Seventh International Symposium on Neutron Capture Therapy for Cancer. p: 166 Zürich, 4-7 September, 1996.
16. Stragliotto G, Fankhauser H. Biodistribution and pharmacokinetics of boron-sulfhydryl for boron neutron capture therapy in patients with intracranial tumors. Neurosurgery 1995;36:285-93.
17. Wheeler FJ. Radiation transport in tissue by Monte Carlo = Version X02. Idaho National Engineering Laboratory report no. EGG-BNCT-11178, 1995.